Charles W. Francis, M.D.

Charles W. Francis, M.D.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 610
Rochester, NY 14642

Administrative: (585) 273-3258
Fax: (585) 273-1042

Professional Bio

Dr. Francis is Professor of Medicine and of Pathology and Laboratory Medicine at the University of Rochester. He obtained his MD degree at the University of Pittsburgh and was then an Intern and Resident in Medicine at the University of North Carolina. He joined the University of Rochester as a Fellow in Hematology in 1976, and he has remained at that institution where he is Director of the Hemostasis and Thrombosis program. Dr. Francis has been recipient of a Clinical Investigator Award from the NHLBI and an Established Investigator Award from the American Heart Association. He has served on numerous NIH Review and Advisory Committees.

He is a past Chairman of the Scientific and Standardization Committee of the ISTH and Program Chair of the XVIIth International Congress on Hemostasis and Thrombosis. He serves as the Editor-in-Chief of Thrombosis Research. Dr. Francis has both clinical and laboratory research interests. Laboratory research has focused on the structure of fibrinogen and fibrin and mechanisms of fibrinolysis. Current work relates to the work of fibrinogen and fibrin in modulating the effects of FGF-2 on endothelial cells. Clinical research has been in the areas of venous thrombosis and new anticoagulants.

Research Bio

Dr. Francis does both clinical and basic research in the areas of thrombosis, hemostasis and vascular biology. Fibrinogen and fibrin have been an area of extensive research. He first described the structures of plasmic degradation products of crosslinked fibrin and developed a molecular model of fibrinolysis. He identified an important structural variant of fibrinogen that differs at the carboxyl terminus of the gamma chain. He was one of the first to demonstrate that ultrasound accelerates enzymatic fibrinolysis, identified the mechanisms responsible and defined the ultrasound parameters for effective fibrinolysis augmentation. Studies in recent years have characterized the interaction of FGF-2, EGF and IL-²

beta with fibrinogen and fibrin. The binding sites for interaction have been identified, and augmented functional activity of FGF-2 and IL-² beta in the bound form demonstrated. Extensive clinical research helped to define the structures of crosslinked fibrin degradation products in fibrinolytic states. Numerous studies have been conducted to improve prophylaxsis of deep vein thrombosis and pulmonary embolism. These have included clinical trials using warfarin, antithrombin, low-molecular-weight heparin and direct thrombin inhibitors. Recent clinical studies have examined risk factors for arterial thrombosis and the effects of thiazolidinediones on lipid and hemostatic risk factors for thrombosis.

Awards & Honors (Local)

Phi Beta Kappa
Alpha Omega Alpha
Established Investigator, American Heart Association
Clinical Investigator Award, National Institutes of Health
Inclusion in "The Best Doctors in America", Woodward/White, Inc, Publishers, 1994, 1995, 1996, 1998, 2000-2006

Recent Journal Articles

Showing the 5 most recent journal articles. 301 available »

2016 Aug 11
Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM, . "Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients." The New England journal of medicine. 2016 Aug 11; 375(6):534-44. Epub 2016 May 27.
2016 Jul 1
Key NS, Khorana AA, Mackman N, McCarty OJ, White GC, Francis CW, McCrae KR, Palumbo JS, Raskob GE, Chan AT, Sood AK. "Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group." Cancer research. 2016 Jul 1; 76(13):3671-5. Epub 2016 Jun 20.
2016 Jul
Kuderer NM, Culakova E, Lyman GH, Francis C, Falanga A, Khorana AA. "A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality." The oncologist. 2016 Jul; 21(7):861-7. Epub 2016 Apr 28.
2016 May
Letertre LR, Gudmundsdottir BR, Francis CW, Gosselin RC, Skeppholm M, Malmstrom RE, Moll S, Hawes E, Francart S, Onundarson PT. "A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma." Journal of thrombosis and haemostasis : JTH. 2016 May; 14(5):1043-53. Epub 2016 Mar 30.
2016 May
Onundarson PT, Arnar DO, Lund SH, Gudmundsdottir BR, Francis CW, Indridason OS. "Fiix-prothrombin time monitoring improves warfarin anticoagulation outcome in atrial fibrillation: a systematic review of randomized trials comparing Fiix-warfarin or direct oral anticoagulants to standard PT-warfarin." International journal of laboratory hematology. 2016 May; 38 Suppl 1:78-90.

Current Appointments

Professor Emeritus - Department of Medicine, Hematology/Oncology (SMD) - Primary

Specialties

Hematology - American Board of Internal Medicine
Internal Medicine - American Board of Internal Medicine

Education

MD | Medicine | Univ Pittsburgh Sch Medicine1973
BA | Biological Science | Johns Hopkins University1969

Post-Doctoral Training & Residency

Fellowship in Hematology at University of Rochester Medical Center07/01/1976 - 06/30/1979
Residency in Internal Medicine at University of North Carolina Hospitals07/01/1974 - 06/30/1976
Internship in Internal Medicine at University of North Carolina Hospitals07/01/1973 - 6/30/1974